Drug Information

Drug General Information
Drug ID
D02BFC
Former ID
DIB011867
Drug Name
Anti-alpha5Beta1-integrin antibody
Drug Type
Antibody
Indication Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] Phase 2 [549992]
Company
PDL BioPharma
Target and Pathway
Target(s) Integrin alpha-5/beta-1 Target Info [528465]
KEGG Pathway Phagosome
PI3K-Akt signaling pathway
Focal adhesion
ECM-receptor interaction
Hematopoietic cell lineage
Regulation of actin cytoskeleton
Bacterial invasion of epithelial cells
Shigellosis
Pertussis
Proteoglycans in cancer
MicroRNAs in cancer
Hypertrophic cardiomyopathy (HCM)
Arrhythmogenic right ventricular cardiomyopathy (ARVC)
Dilated cardiomyopathy
Reactome Elastic fibre formation
Fibronectin matrix formation
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Cell surface interactions at the vascular wall
Basigin interactions
Molecules associated with elastic fibres
Integrin cell surface interactions
Laminin interactions
Syndecan interactions
ECM proteoglycans
Other semaphorin interactions
Localization of the PINCH-ILK-PARVIN complex to focal adhesions
CHL1 interactions
RHO GTPases Activate Formins
WikiPathways Focal Adhesion
Extracellular matrix organization
Elastic fibre formation
Arrhythmogenic Right Ventricular Cardiomyopathy
Integrin-mediated Cell Adhesion
L1CAM interactions
Integrin cell surface interactions
Cell surface interactions at the vascular wall
References
Ref 549992Phase II study of volociximab (M200), an {alpha}5?1 anti-integrin antibody in refractory metastatic clear cell renal cell cancer (RCC), Journal of Clinical Oncology, Vol 24, No 18S (June 20 Supplement), 2006: 4535.
Ref 528465Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol. 2006;5(4):273-86.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.